RecruitingPhase 1NCT06774963

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

Sponsor

NextCure, Inc.

Enrollment

145 participants

Start Date

Jan 7, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Biliary Tract Cancer Ovarian Cancer Endometrial Cancer

Summary

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an early-phase safety study testing a new drug called LNCB74 in people with advanced solid tumors (cancers that form solid masses and cannot be surgically removed). The goal is to find the safest dose and learn how the body handles the drug. **You may be eligible if...** - You are 18 years or older - You have a confirmed advanced solid tumor cancer that cannot be surgically removed or has spread - Your cancer is measurable on scans - You are in good general health (ECOG performance status assessed by your doctor) - You are able to provide a tumor tissue sample - You are not pregnant or breastfeeding, and you agree to use contraception if applicable **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are unable to provide tumor tissue - You have serious health conditions that would make the drug unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLNCB74

LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.

Locations(14)

Hoag Family Cancer Institute

Newport Beach, California, United States

St. Elizabeth Healthcare

Edgewood, Kentucky, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Washington University, Siteman Cancer Center

St Louis, Missouri, United States

John Theurer Cancer Ctr at Hackensack Univ. Med Ctr.

Hackensack, New Jersey, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Cleveland Clinic Taussig Cancer Institute

Cleveland, Ohio, United States

Sidney Kimmel Comprehensive Center at Jefferson

Philadelphia, Pennsylvania, United States

UPMC

Pittsburgh, Pennsylvania, United States

MD Anderson

Houston, Texas, United States

NEXT Oncology

San Antonio, Texas, United States

UT Health San Antonio - MD Anderson Cancer Center

San Antonio, Texas, United States

Intermountain/LDS Hospital Ph 1 Research Program

Salt Lake City, Utah, United States

Inova Schar Cancer Institute

Falls Church, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06774963

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

Genomic Services Research Program

NCT025959571 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations